Erythropoiesis-stimulating agents in chronic kidney disease: What have we learned in 25 years?
نویسندگان
چکیده
منابع مشابه
Price cap regulation : what have we learned from 25 years of experience in the telecommunications industry ?
Price cap regulation (PCR) has now been employed in the telecommunications industry for more than a quarter century. We review the experience with PCR and offer an explanation for its popularity. PCR’s design flexibility, its ability to limit undesirable strategic behavior, declining industry costs, and developing competition all enhanced the appeal of PCR. We also review some surprises that ha...
متن کاملTakotsubo Cardiomyopathy: What we have Learned in the Last 25 Years? (A Comparative Literature Review)
We performed a comparative literature review, to elucidate the major features of the Takotsubo (stress) cardiomyopathy (TCM) collected in last 25 years. TCM is characterized by left- or biventricular apical ballooning with a clinical presentation, electrocardiographic abnormalities, and biomarker profils similar to those seen in acute myocardial infarction. Epidemiological studies have shown th...
متن کاملPosttraumatic stress disorder: what have we learned in 3000 years?
In his 1994 masterpiece, Achilles in Vietnam, Dr. Shay taught us that posttraumatic stress disorder could, at least in part, be the result of ‘‘betrayal of what’s right,’’ informed by the lessons of Homer’s Iliad, written nearly 3000 years ago. The timeless lessons brought on by the ancient Greek stories of Ajax, Achilles, and Odysseus indicate great insight into the human condition and the psy...
متن کاملFifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?
Losartan, the first AT1 receptor blocker (ARB), was FDA approved 15 years ago. During those years, researchers and clinicians have developed a growing base of knowledge on the benefits of losartan, particularly for hypertension and renal disease. These benefits include decreasing proteinuria, slowing the progression of diabetic nephropathy, controlling hypertension, and decreasing stroke risk i...
متن کاملHypertrophic cardiomyopathy: what have we learned in fifty years?
F ive decades have already passed since the first modern description of hypertrophic cardiomyopathy (HCM) by the British pathologist Donald Teare. After its half-century history, the secrets of the disease have begun to be revealed; however, there is still much that we do not know. HCM is the disease with the largest heterogeneity in clinical cardiology, in the sense of its clinical manifestati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the Formosan Medical Association
سال: 2014
ISSN: 0929-6646
DOI: 10.1016/j.jfma.2013.09.004